EKSO Ekso Bionics Holdings Inc

Ekso Bionics to Report First Quarter 2023 Financial Results on April 27, 2023

Ekso Bionics to Report First Quarter 2023 Financial Results on April 27, 2023

SAN RAFAEL, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2023 after the close of trading on Thursday, April 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

A live webcast of the event will be available in the “Investors” section of the Company’s website at , or by . Investors interested in listening to the conference call may do so by dialing 877-407-3036 for domestic callers or 201-378-4919 for international callers.

A webcast replay will also be available on the Company’s website for one month following the completion of the call.

About Ekso Bionics® 

Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: or follow @EksoBionics on Twitter.

Contact:

David Carey

212-867-1768



EN
20/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ekso Bionics Holdings Inc

 PRESS RELEASE

Ekso Bionics Reports Second Quarter 2025 Financial Results

Ekso Bionics Reports Second Quarter 2025 Financial Results SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group (“Bionic P&O”) as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into the NVIDIA Connect program, suppor...

 PRESS RELEASE

Ekso Bionics to Report Second Quarter 2025 Financial Results on July 2...

Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter of 2025 after the close of trading on Monday, July 28, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments...

 PRESS RELEASE

Virtual eksoUniversity to Support Continuing Education of PTs and PTAs...

Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country On-demand courses already approved for CEUs in over 30 states SAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, is pleased to announce the launch of , a new platform providing continuing education courses to physical therapists (“PTs”) and physical therapy assistants (“PTAs”) across the country. Most states require healthcare professionals t...

 PRESS RELEASE

Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit

Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company into the NVIDIA Connect Program SAN RAFAEL, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has successfully demonstrated initial proof-of-concept in ...

 PRESS RELEASE

Ekso Bionics Announces New Effective Date of Reverse Stock Split

Ekso Bionics Announces New Effective Date of Reverse Stock Split SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Ma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch